Navigation Links
Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling

Dr. Bill Poland Will Discuss Best Practices in HCV and HIV Drug-Disease Modeling and Simulation to Support Clinical Drug Development Decision


MOUNTAIN VIEW, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, will speak to members of the pharmaceutical and biotechnology industries via web conference on HCV/HIV drug-disease modeling on Thursday, February 28, 2008, at 1:00 p.m. Eastern Standard Time (10:00 a.m. PST).

Dr. Poland's presentation, entitled "Portable Concepts for HCV and HIV Drug-Disease Modeling and Simulation" will discuss the use and strategic value of quantitative modeling and simulation to design, predict and improve clinical trial outcomes for HCV and HIV drugs. Applied case examples will illustrate that despite important differences between HCV and HIV, such as the potential to cure HCV and faster HCV dynamics, HCV trial outcomes, like those for HIV, can be predicted and improved by model-informed design. More information about this event is available at

"HCV and HIV present special therapeutic challenges to drug development teams, including the emergence of resistance, complex pharmacokinetics, and patient compliance," said Shawn O'Connor, president, CEO and chairman of Pharsight. "To support planning and quantitative decision-making for antiviral development, it is important to leverage synergies wherever possible in the complexities of viral dynamics modeling. HIV and HCV drug development programs can benefit from Pharsight's predictive modeling methods and extensive knowledge of the competitive treatment landscape. Model-based approaches can lead to enhanced clinical trial designs and in developing strategies to optimize tradeoffs such as that between patient compliance and dosing regimen, as well as inform better clinical program investment decisions."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA and Pharsight Continue to Collaborate Under CRADA
2. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
3. Pharsight Achieves $7.3 Million in Quarterly Revenue
4. Pharsight Expands Global Consulting Services Teams
5. Pharsight to Host European Software Conference
6. Pharsight Files Application for Nasdaq Capital Market Listing
7. FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges
8. Portico Systems Offers Webinar Series to Share Provider Network Management Best Practices
9. Uncover Key Competitive Intelligence Insights in Webinars Hosted by Best Practices
10. GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C
11. Grapefruit compound may help combat hepatitis C infection
Post Your Comments:
(Date:11/27/2015)... ... , ... A simply groundbreaking television series, "Voices in America", which is hosted ... array of issues that are presently affecting Americans. Dedicated to providing the world with ... changing the subjects consumers focus on, one episode at a time. , In ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel ... self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with ... work with any font, giving users limitless opportunities to stylize and create designs ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
(Date:11/26/2015)... 2015 ) has ... of High Viscosity Drugs" report to their ... the addition of the "Self Administration of ... --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" report ...
Breaking Medicine Technology: